Drug
Pemafibrate clinical trials
- studies test it
- 14
- open now
- 2
- in phase 3
- 3
- first study started
- 2014
Keep track of what changes. Save the pemafibrate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
14 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 2 |
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 3
- Phase 3
- 3
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 2
Kowa Research Institute, Inc. (8) · Kowa Company, Ltd. (4) · Tokyo Women's Medical University (1) · Jaeb Center for Health Research (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses pemafibrate is read from its arms, and is right about nine times in ten.
Testing it · 14
- Pemafibrate for Symptomatic ICAS RCTRecruitingNot applicableTokyo Women's Medical UniversityNCT07562178Written as Pemafibrate
- A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to StatinsRecruitingPhase 4Kowa Company, Ltd.NCT07634484Written as Pemafibrate 0.2 mg/day
- Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.CompletedPhase 2Kowa Research Institute, Inc.NCT06247735Written as K-808 (Dose A)
- A Clinical Pharmacology Study of K-877 Controlled Release TabletCompletedPhase 2Kowa Company, Ltd.NCT04079530Written as K-877 IR 0.2 mg/day
- Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)TerminatedPhase 3Kowa Research Institute, Inc.NCT03071692Written as K-877
- A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-CCompletedPhase 3Kowa Company, Ltd.NCT04998981Written as K-877 0.1 mg tablet
- A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.CompletedPhase 1Kowa Research Institute, Inc.NCT06525311Written as K-808
- Study to Assess the Food Effect of K-877 in Healthy Adult VolunteersCompletedPhase 1Kowa Research Institute, Inc.NCT04742218Written as K-877
- A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)CompletedPhase 2Kowa Company, Ltd.NCT03350165Written as K-877
- Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult VolunteersCompletedPhase 1Kowa Research Institute, Inc.NCT04237597Written as K-877
- PROMINENT-Eye Ancillary Study (Protocol AD)TerminatedPhase 3Jaeb Center for Health ResearchNCT03345901Written as Pemafibrate
- Drug-Drug Interaction Study to Assess the Effects of Multi Dose Clopidogrel on the Pharmacokinetics of Single-Dose K-877 in Healthy Adult VolunteersCompletedPhase 1Kowa Research Institute, Inc.NCT02922465Written as K-877
- Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult VolunteersCompletedPhase 1Kowa Research Institute, Inc.NCT02719431Written as K-877
- Drug-Drug Interaction Study in Health Adult VolunteersCompletedPhase 1Kowa Research Institute, Inc.NCT02273986Written as K-877
Given in every arm · 6 — pemafibrate is usual care beside what is tested
- Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal FunctionCompletedPhase 3Kowa Research Institute, Inc.NCT03001817Written as K-877
- Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal ImpairmentCompletedPhase 3Kowa Research Institute, Inc.NCT03011450Written as K-877
- Drug-Drug Interaction Study in Healthy Adult VolunteersCompletedPhase 1Kowa Research Institute, Inc.NCT02275962Written as K-877
- Drug-Drug Interaction Study in Healthy Adult VolunteersCompletedPhase 1Kowa Research Institute, Inc.NCT02276001Written as K-877
- Drug-Drug Interaction Study in Healthy Adult VolunteersCompletedPhase 1Kowa Research Institute, Inc.NCT02275975Written as K-877
- Drug-Drug Interaction Study in Healthy Adult VolunteersCompletedPhase 1Kowa Research Institute, Inc.NCT02275988Written as K-877
Codes
What other systems call pemafibrate · ClinicalTrials.gg INT005434
- UNII (FDA) 17VGG92R23PEMAFIBRATEConfirmed FDA, Wikidata
- Wikidata Q27251943pemafibrateConfirmed FDA, Wikidata
- NCI Thesaurus C166474PemafibrateOne source FDA
- DrugBank DB15212One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 17VGG92R23 | PEMAFIBRATE | Confirmed FDA, Wikidata |
| Wikidata | Q27251943 | pemafibrate | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166474 | Pemafibrate | One source FDA |
| DrugBank | DB15212 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.